SMS Pharmaceuticals Share Price Today | Stock Price & SMS Pharmaceuticals Share Screener
As of November 19, 2026, the live SMS Pharmaceuticals share price (NSE: SMSPHARMA) is ₹481.35 on NSE and ₹482.35 on BSE, up 0.95% from the previous close, with shares trading between ₹467.35 and ₹484.00 in today's trading session, and a 52-week range of ₹271.55–₹525.50. Track SMS Pharmaceuticals market worth to gauge the company's total market size. Use the SMS Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today SMS Pharmaceuticals opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹317 and net income of ₹40, with EBITDA of ₹69, an operating margin of 21.0% and a profit margin of 12.6%.
SMS Pharmaceuticals Share Price Chart
Track the current stock price of SMS Pharmaceuticals with an interactive chart. Analyse SMSPHARMA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete SMS Pharmaceuticals stock quote in one place.
The quote of ₹481.35 sits between the 52-week low of ₹271.55 and the 52-week high of ₹525.50, and the latest session moved 0.95% from the previous close.
SMS Pharmaceuticals Company Profile - Fundamental Screener
Screen SMS Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SMSPHARMA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE812G01025.
Company Details
Classification
Identifiers and Leadership
SMS Pharmaceuticals Balance Sheet Screener
Screen SMSPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹1,362, up from ₹1,153 in 2025.
Latest statistics put total assets at ₹1,362 and shareholder funds at ₹786, with a leverage ratio of 0.47.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 1,362 | 1,153 | 1,034 | 880 | 860 | 812 | 608 | 559 | 503 | 493 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 534 | 533 | 437 | 412 | 438 | 457 | 281 | 281 | 279 | 291 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 224 | 189 | 166 | 164 | 193 | 206 | 115 | 94 | 97 | 91 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 786 | 640 | 536 | 461 | 470 | 411 | 348 | 322 | 285 | 255 |
| Share Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Reserves & Surplus | 776 | 615 | 499 | 452 | 462 | 402 | 340 | 314 | 276 | 246 |
SMS Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen SMS Pharmaceuticals income statement and profit fundamentals. Analyze SMSPHARMA quarterly results. SMS Pharmaceuticals reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Sept, revenue was ₹317 and net profit was ₹40, equal to earnings per unit of ₹4.26, at an operating margin of 21%.
In that period expenses were ₹248, interest cost ₹6 and tax ₹13. The next period listed, 2026-Jun, shows revenue of ₹209 and net profit of ₹21.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 317 | 209 | 241 | 214 | 244 | 197 | 250 | 176 | 198 | 166 | 248 | 163 | 167 | 136 | 151 |
| Expenses | 248 | 166 | 198 | 167 | 194 | 157 | 207 | 140 | 165 | 131 | 212 | 133 | 139 | 109 | 126 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 69 | 43 | 43 | 47 | 50 | 40 | 42 | 35 | 33 | 35 | 35 | 31 | 29 | 27 | 25 |
| Operating Profit % | 21.00% | 20.00% | 17.00% | 21.00% | 20.00% | 20.00% | 16.00% | 19.00% | 16.00% | 20.00% | 14.00% | 18.00% | 17.00% | 19.00% | 16.00% |
| Depreciation | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 |
| Interest | 6 | 6 | 5 | 6 | 6 | 6 | 5 | 4 | 5 | 5 | 6 | 6 | 6 | 6 | 6 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 53 | 27 | 27 | 31 | 34 | 24 | 29 | 22 | 20 | 22 | 22 | 17 | 15 | 13 | 11 |
| Tax | 13 | 6 | -6 | 8 | 9 | 4 | 8 | 4 | 5 | 5 | 5 | 5 | 3 | 3 | 4 |
| Net Profit | 40 | 21 | 33 | 24 | 25 | 21 | 20 | 18 | 14 | 17 | 17 | 12 | 12 | 9 | 6 |
| EPS | 4.26 | 2.23 | 3.58 | 2.59 | 2.84 | 2.31 | 2.40 | 2.15 | 1.67 | 1.95 | 2.04 | 1.36 | 1.39 | 1.10 | 0.73 |
SMS Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen SMSPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹59, and net cash flow was an inflow of ₹5.
Over the same period, investing activities used ₹131 and financing activities provided ₹76.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 59 | 82 | 50 | 23 | 45 | 90 | 40 | 50 | 32 | 74 |
| Investing Activities | -131 | -123 | -52 | -30 | -27 | -152 | -43 | -35 | -17 | -39 |
Financing and Net Cash | ||||||||||
| Financing Activities | 76 | 47 | 31 | -32 | -12 | 92 | -2 | -13 | -15 | -33 |
| Net Cash Flow | 5 | 5 | 29 | -39 | 6 | 31 | -5 | 2 | 0 | 1 |
SMS Pharmaceuticals Shareholding Pattern Screener
See SMS Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check SMS Pharmaceuticals promoter holding and ownership changes for SMSPHARMA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 68.07%, foreign institutions 0.31%, domestic institutions 3.02% and the public 23.17%, spread across 32,397 shareholders.
The shareholder count was 32,397 in 2026-Mar, compared with 31,489 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 68.07% | 68.07% | 68.07% | 66.26% | 66.26% | 68.07% | 68.07% | 64.67% |
Institutional Investors | ||||||||
| FII Holding | 0.31% | 0.65% | 1.18% | 0.08% | 0.03% | 0.28% | 0.04% | 0.17% |
| DII Holding | 3.02% | 2.83% | 0.20% | 2.43% | 3.03% | 2.88% | 3.21% | 1.98% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.17% | 24.04% | 25.86% | 26.35% | 25.89% | 24.02% | 24.08% | 27.93% |
| Other Holding | 5.43% | 4.41% | 4.71% | 4.87% | 4.78% | 4.76% | 4.61% | 5.25% |
| Shareholder Count | 32,397 | 31,489 | 34,904 | 35,332 | 33,652 | 33,009 | 34,378 | 30,140 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by SMS Pharmaceuticals. SMS Pharmaceuticals dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.40 per unit for 2026-March, a yield of 0.08%, compared with ₹0.40 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.40, ₹0.40 and ₹0.40 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.40 | 0.08% |
| 2025-March | ₹0.40 | 0.11% |
| 2024-March | ₹0.40 | 0.19% |
| 2023-March | ₹0.30 | 0.17% |
| 2022-March | ₹0.30 | 0.53% |
| 2021-March | ₹0.30 | 0.32% |
| 2020-March | ₹0.25 | 0.20% |
| 2019-March | ₹0.25 | 0.93% |
| 2018-March | ₹0.25 | 0.40% |
| 2017-March | ₹0.20 | 0.27% |
SMS Pharmaceuticals Stock Index Membership - Nifty & Sensex
See which indices include SMS Pharmaceuticals stock. Check SMSPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 2 indices, including BSE INDEX BSE HC.
Among the benchmarks tracked are BSE INDEX BSE HC, BSE INDEX SMLCAP.
Complete Index List
SMS Pharmaceuticals Market Events Screener - Corporate Actions
Get SMS Pharmaceuticals corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check SMS Pharmaceuticals stock events that may affect SMSPHARMA share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 4, 2026, with a record date of November 4, 2026.
It is followed by Annual General Meeting dated September 29, 2026 and Dividend dated September 22, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-04 | 2026-11-04 | Quarterly Result Announcement | NA | 16.01% |
| 2026-09-29 | 2026-09-29 | Annual General Meeting | NA | 23.25% |
| 2026-09-22 | 2026-09-22 | Dividend | ₹ 0.40 /share | 9.55% |
| 2026-07-31 | 2026-07-31 | Quarterly Result Announcement | NA | -1.69% |
| 2026-05-22 | 2026-05-22 | Quarterly Result Announcement | NA | 6.36% |
| 2026-02-07 | 2026-02-07 | Quarterly Result Announcement | NA | 0.44% |
| 2025-11-08 | 2025-11-08 | Quarterly Result Announcement | NA | 0.91% |
| 2025-09-29 | 2025-09-29 | Annual General Meeting | NA | 12.38% |
| 2025-09-22 | 2025-09-22 | Dividend | ₹ 0.40 /share | 8.19% |
| 2025-08-09 | 2025-08-09 | Quarterly Result Announcement | NA | -2.17% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 3.00% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | -2.50% |
| 2024-11-08 | 2024-11-08 | Quarterly Result Announcement | NA | 3.84% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 12.37% |
| 2024-09-23 | 2024-09-23 | Dividend | ₹ 0.40 /share | 75.63% |
SMS Pharmaceuticals Competitors Screener - Peer Stocks Comparison
Screen SMSPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 448,076 | 41.10 | 61,674 | 12.69% | 11,565 | 59.98 |
| Divis Laboratories | 294,139 | 90.70 | 11,067 | 13.95% | 2,568 | 67.88 |
| Torrent Pharmaceuticals | 178,438 | 84.50 | 13,886 | 20.34% | 2,138 | 49.31 |
| Laurus Labs | 119,949 | 98.10 | 6,868 | 22.01% | 890 | 49.19 |
| Zydus Life Science | 118,902 | 27.60 | 27,658 | 17.64% | 5,026 | 52.87 |
| Dr Reddys Laboratories | 115,011 | 41.70 | 35,059 | 3.90% | 4,158 | 69.34 |
| Cipla | 112,656 | 39.40 | 29,045 | 2.24% | 3,870 | 55.82 |
| Mankind Pharma | 108,490 | 48.40 | 14,636 | 14.85% | 1,938 | 63.62 |
| Aurobindo Pharma | 103,223 | 26.40 | 34,145 | 5.56% | 3,503 | 60.38 |
| Lupin | 90,393 | 17.30 | 29,039 | 26.75% | 5,356 | 44.23 |
SMS Pharmaceuticals Company Announcements - News & Reports Screener
Screen SMSPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 14, 2026.
The next most recent announcements are dated November 5, 2026 and November 5, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-14 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-11-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-11-04 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-11-04 | Financial Results And Change In Company Secretary | - |
| 2026-11-04 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-11-04 | Board Meeting Outcome for Outcome Of Board Meeting And Financial Results | - |
| 2026-11-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-31 | Receipt Of Order From Income Tax Department | - |
| 2026-10-31 | Order Received From The Income Tax Department | - |
| 2026-10-30 | Loan Agreement With The Subsidiary Of The Company | - |
| 2026-10-28 | Board Meeting Intimation for Approval Of Financial Results For The Quarter Ended 30 September 2026 | - |
| 2026-10-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-09-30 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-29 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-24 | Closure of Trading Window | - |
| 2026-09-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-09-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-04 | Letter To Shareholders Regarding Annual Report | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹481.35, within a 52-week range of ₹271.55 to ₹525.50. The P/E ratio is 40.70 and the P/B ratio is 5.65, with earnings per unit of ₹9.58. Market capitalisation stands at ₹4,556.17 Cr and the dividend yield is 0.08%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.